Truist Securities Reiterates Buy on Xencor, Raises Price Target to $29
9/28/2026
Impact: 70
Healthcare
Truist Securities analyst Gregory Renza has reiterated a Buy rating on Xencor (NASDAQ: XNCR) and increased the price target from $27 to $29.
AI summary, not financial advice
Share: